The Novartis (NOVN: VX) division Sandoz has added to the case for European prescribers to switch rheumatoid arthritis (RA) patients taking AbbVie's (NYSE: ABBV) Humira (adalimumab) to its biosimilar.
Data presented at EULAR from the Phase III ADMYRA trial shows that the efficacy and safety of Sandoz’s copy, branded Hyrimoz, matches that of the reference drug.
There were no clinically-meaningful differences between the two in patients with moderate-to-severe RA with inadequate response to disease modifying antirheumatic drugs, including methotrexate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze